CAR-T cell manufacturing: Major process parameters and next-generation strategies

被引：89

作者：

Ayala Ceja, Melanie ^{[1
]}

Khericha, Mobina ^{[1
]}

Harris, Caitlin M. ^{[1
]}

Puig-Saus, Cristina ^{[2
,3
,4
]}

Chen, Yvonne Y. ^{[1
,3
,4
,5
]}

机构：

[1] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

[4] Univ Calif Los Angeles, Parker Inst Canc Immunotherapy Ctr, Los Angeles, CA 90095 USA

[5] Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA

来源：

JOURNAL OF EXPERIMENTAL MEDICINE | 2024年 / 221卷 / 02期

关键词：

CENTRAL MEMORY; IN-VIVO; LISOCABTAGENE MARALEUCEL; HEMATOPOIETIC STEM; SLEEPING-BEAUTY; SITE SELECTION; RECEPTOR; THERAPY; CD8(+); CD4(+);

D O I：

10.1084/jem.20230903

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The success of CAR-T cell therapies is dependent on effective cell manufacturing that impacts product safety, efficacy, and patient accessibility. Here, we discuss major process parameters of autologous CAR-T cell manufacturing, regulatory considerations, and emerging technologies in therapeutic cell manufacturing. Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.

引用

页数：14

共 156 条

[1] Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study [J].

Abramson, Jeremy S. ;

Solomon, Scott R. ;

Arnason, Jon ;

Johnston, Patrick B. ;

Glass, Bertram ;

Bachanova, Veronika ;

Ibrahimi, Sami ;

Mielke, Stephan ;

Mutsaers, Pim ;

Hernandez-Ilizaliturri, Francisco ;

Izutsu, Koji ;

Morschhauser, Franck ;

Lunning, Matthew ;

Crotta, Alessandro ;

Montheard, Sandrine ;

Previtali, Alessandro ;

Ogasawara, Ken ;

Kamdar, Manali .

BLOOD, 2023, 141 (14) :1675-1684

[2] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[3] In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes [J].

Agarwal, Shiwani ;

Hanauer, Julia D. S. ;

Frank, Annika M. ;

Riechert, Vanessa ;

Thalheimer, Frederic B. ;

Buchholz, Christian J. .

MOLECULAR THERAPY, 2020, 28 (08) :1783-1794

[4] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy [J].

Al Hadidi, Samer ;

Szabo, Aniko ;

Esselmann, Jean ;

Hammons, Lindsay ;

Hussain, Munawwar ;

Ogunsesan, Yetunde ;

Thalambedu, Nishanth ;

Khan, Fatima ;

Sethi, Jaskirat ;

Janardan, Abhishek ;

Radhakrishnan, Sabarinath Venniyil ;

Thanendrarajan, Sharmilan ;

Schinke, Carolina ;

Dhakal, Binod ;

Janz, Siegfried ;

Chhabra, Saurabh ;

D'Souza, Anita ;

Zangari, Maurizio ;

van Rhee, Frits ;

Mohan, Meera .

BONE MARROW TRANSPLANTATION, 2023, 58 (04) :443-445

[5] Functionality and Cell Senescence of CD4/CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform [J].

Aleksandrova, Krasimira ;

Leise, Jana ;

Priesner, Christoph ;

Melk, Anette ;

Kubaink, Fanni ;

Abken, Hinrich ;

Hombach, Andreas ;

Aktas, Murat ;

Essl, Mike ;

Buerger, Iris ;

Kaiser, Andrew ;

Rauser, Georg ;

Jurk, Marion ;

Goudeva, Lilia ;

Glienke, Wolfgang ;

Arseniev, Lubomir ;

Esser, Ruth ;

Koehl, Ulrike .

TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (01) :47-54

[6] CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome [J].

Arcangeli, Silvia ;

Bove, Camilla ;

Mezzanotte, Claudia ;

Camisa, Barbara ;

Falcone, Laura ;

Manfredi, Francesco ;

Bezzecchi, Eugenia ;

El Khoury, Rita ;

Norata, Rossana ;

Sanvito, Francesca ;

Ponzoni, Maurilio ;

Greco, Beatrice ;

Moresco, Marta Angiola ;

Carrabba, Matteo G. ;

Ciceri, Fabio ;

Bonini, Chiara ;

Bondanza, Attilio ;

Casucci, Monica .

JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (12)

[7] Next-Generation Manufacturing Protocols Enriching TSCMCAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients [J].

Arcangeli, Silvia ;

Falcone, Laura ;

Camisa, Barbara ;

De Girardi, Federica ;

Biondi, Marta ;

Giglio, Fabio ;

Ciceri, Fabio ;

Bonini, Chiara ;

Bondanza, Attilio ;

Casucci, Monica .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[8] Single-cell antigen-specific landscape of CART infusion product identifies determinants of CD19-positive relapse in patients with ALL [J].

Bai, Zhiliang ;

Woodhouse, Steven ;

Zhao, Ziran ;

Arya, Rahul ;

Govek, Kiya ;

Kim, Dongjoo ;

Lundh, Stefan ;

Baysoy, Alev ;

Sun, Hongxing ;

Deng, Yanxiang ;

Xiao, Yang ;

Barrett, David M. ;

Myers, Regina M. ;

Grupp, Stephan A. ;

June, Carl H. ;

Fan, Rong ;

Camara, Pablo G. ;

Melenhorst, J. Joseph .

SCIENCE ADVANCES, 2022, 8 (23)

[9]

Balke-Want H, 2023, Immunooncol Technol, V18, P100375, DOI 10.1016/j.iotech.2023.100375

[10] YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update [J].

Barba, Pere ;

Kwon, Mi ;

Briones, Javier ;

Jaeger, Ulrich ;

Bachy, Emmanuel ;

Blaise, Didier ;

Boissel, Nicolas ;

Kato, Koji ;

Shah, Nirav N. ;

Frigault, Matthew ;

Riedell, Peter A. ;

Shune, Leyla O. ;

Teshima, Takanori ;

Ciceri, Fabio ;

Pearson, David ;

Orlando, Elena J. ;

Yi, Lan ;

Davis, Jaclyn ;

Masood, Aisha ;

Flinn, Ian W. ;

Dickinson, Michael .

BLOOD, 2022, 140 :1056-1059

← 1 2 3 4 5 6 7 8 9 10 →